Background
==========

Insomnia is a serious public health problem because of its high prevalence and treatment challenges \[[@b1-medscimonit-26-e921831]\]. Epidemiological studies of the general population show that about one-third of adults complain of insomnia symptoms \[[@b2-medscimonit-26-e921831]\]. The self-report rate of sleep problems in one study was 55.8%, of which 18.0% often had sleep problems \[[@b3-medscimonit-26-e921831]\]. More and more studies have shown that insomnia or short sleep time or lack of sleep have an adverse impact on personal health \[[@b4-medscimonit-26-e921831]\]. Such adverse impacts include increased hypertension, subclinical cardiovascular disease, coronary heart disease and heart failure, cardiovascular disease morbidity and mortality \[[@b5-medscimonit-26-e921831]--[@b8-medscimonit-26-e921831]\]. In addition, insomnia has been found to have an association with cognitive impairment, decreased quality of life, reduced work efficiency, mental illness complications, higher medical costs, and higher risk of death \[[@b9-medscimonit-26-e921831]\]. The correlation between insomnia and these conditions is not clear, which is mainly attributed to little knowledge on the causes of insomnia.

The main pathophysiological mechanisms of insomnia are linked to cognitive, self-referential processes, affective, and sleep-wake-promoting changes in related structures or circuits \[[@b10-medscimonit-26-e921831]--[@b12-medscimonit-26-e921831]\]. In addition, high frequency cortical dynamics, brain glucose metabolism, impaired systemic metabolic rate and heart rate variability, and increased cortisol and norepinephrine levels were also contributors \[[@b13-medscimonit-26-e921831]--[@b15-medscimonit-26-e921831]\]. Recent evidence has indicated that neuregulin-1 (NRG1) and its ErbB receptors played an essential role in neural development and function \[[@b16-medscimonit-26-e921831]\]. The presence of ErbB receptors in the brainstem is involved in motor function \[[@b17-medscimonit-26-e921831]\]. More importantly, many observational studies have found that chronic low-grade inflammation is one of the potential pathways leading to adverse health consequences of insomnia \[[@b18-medscimonit-26-e921831],[@b19-medscimonit-26-e921831]\]. Sleep insufficiency and sleep interruption experiments have shown subsequent elevations in blood pressure and inflammatory cytokines, including C-reactive protein (CRP), interleukin (IL)-6, and tumor necrosis factor-alpha (TNF-alpha) \[[@b20-medscimonit-26-e921831]--[@b22-medscimonit-26-e921831]\]. The longer course of extreme sleep was also associated with CRP, IL-6 and TNF-alpha \[[@b23-medscimonit-26-e921831]\]. Studies support that chronic low-grade inflammation might be the last common pathway to adult morbidity \[[@b24-medscimonit-26-e921831]\]. Therefore, it is necessary to identify the molecular mechanisms of insomnia and to diagnose and treat these adverse health outcomes early in life.

Current use of hypnotics was seen in 7.9% of adults in a study of a representative sample of Norwegian adults \[[@b25-medscimonit-26-e921831]\]. In fact, effective treatment for insomnia exists. However, the treatment of insomnia is not standardized \[[@b26-medscimonit-26-e921831]\]. Treatment of insomnia is challenging because both drug and non-drug therapies have limitations \[[@b27-medscimonit-26-e921831]\]. There is no doubt about the effect of cognitive-behavior therapy for insomnia (CBT-I) on insomnia, but the feasibility and cost-effectiveness of CBT-I makes it difficult for various individuals with chronic insomnia to benefit from this approach \[[@b28-medscimonit-26-e921831]\]. Benzodiazepines increase the risk of cognitive impairment and dementia by 50% \[[@b29-medscimonit-26-e921831]\]. Traditional Chinese medicine has been widely studied for its long-term efficacy and safety in the treatment of insomnia \[[@b30-medscimonit-26-e921831],[@b31-medscimonit-26-e921831]\]. The herbs Suanzaoren, Fuling, and Gancao have been found to have potential pharmacological mechanisms for insomnia \[[@b32-medscimonit-26-e921831]\]. Surprisingly, traditional Chinese medicine has been reported to have a good therapeutic effect on elderly insomnia patients with hypertension, which helps to reduce the risk of polypharmacy \[[@b33-medscimonit-26-e921831]\]. Previous studies have shown that Jiao-Tai-Wan, composed of berberine and other herbal formulas, can improve insomnia in rats \[[@b34-medscimonit-26-e921831],[@b35-medscimonit-26-e921831]\]. The specific effect and mechanism of berberine are not clear.

The aim of our study was to identify the molecular mechanisms of insomnia by transcriptome sequencing based on an insomnia rat model. Then the restorative effects and targets of berberine on insomnia rats were evaluated by molecular indicators. The results of this study will further provide a theoretical foundation for the clinical application of berberine in the treatment of insomnia.

Material and Methods
====================

Construction of insomnious rat model and treatment protocol
-----------------------------------------------------------

Healthy male specific-pathogen-free (SPF) grade adult 2-month-old Sprague Dawley (SD) rats weighed 200±20 g and were purchased from the Laboratory Animal Center of Xinjiang Medical University, license number: SCXK (new) 2018-0002. The rats were provided with water freely during feeding. Sixty SD rats were weighed and divided into 6 groups according to a random number table, 10 rats in each group. Insomnia rat model was established as follows: caffeine (Xinjiang Pharmaceutical Factory of China Pharmaceutical Group) with saline solution (60 mg/kg) was injected intraperitoneally for 7 days. Then parachlorophenylalanine (PCPA, Sigma) suspension (300 mg/kg) was prepared with dilute alkaline saline and injected intraperitoneally for 3 days. The normal control group was given intraperitoneal injection of normal saline. Berberine (Shanghai Pharmaceutical Chifeng Mengxin Pharmaceutical) was given in 3 doses: low dose (50 mg/kg) group, moderate dose (100 mg/kg) group, and high dose (200 mg/kg) group; and the diazepam (Beijing Yimin Pharmaceutical) group (0.9 mg/kg) were intragastrically administered for 7 days. Then other experiments were carried out, including body weight measurements in each group.

Moral statement
---------------

All experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals and all experimental protocols were approved by the Animals Ethics Committee of the Xinjiang Medical University (No. IACUC20190116-01).

Water maze
----------

The wall of the pool was marked with 4 water entry points: east, south, west, and north. The platform was hidden 2.5 cm below the water surface and placed in the third quadrant. The midpoint of each quadrant arc was selected as the fixed entry point of the quadrant. Rats arrestment on the platform for 10 seconds was regarded as a sign of success in finding the platform. If the platform was discovered within 120 seconds, the next quadrant experiment was carried out after 10 second detention on the platform. On the sixth day, the space exploration experiment was conducted, and the platform was withdrawn. The number of times each rat crossed the original platform within 120 seconds was recorded.

Sodium pentobarbital
--------------------

The rats in each group were intraperitoneally injected with sodium pentobarbital (Sigma) 35 mg/kg, and the sleep latency and duration of each rat were recorded. Rats were supine on a flat plate and maintained for more than 60 seconds as the righting reflex disappeared. Sleep latency lasted from injection of pentobarbital sodium to the disappearance of righting reflex. Sleep duration ranged from the disappearance of the righting reflex to the recovery of spontaneous movement.

Enzyme-linked immunosorbent assay (ELISA)
-----------------------------------------

Rats were anesthetized by intraperitoneal injection of 10% chloral hydrate (Chengdu Kelong Chemical Reagent Factory) at a rate of 3.0 mg/kg. There were no exhibited signs of peritonitis after the administration of 10% chloral hydrate in rats. Blood samples were collected from abdominal aorta immediately after anesthesia and the contents of atrial natriuretic peptide (ANP; Jianglai Biology), B-type natriuretic peptide (BNP; Jianglai Biology) and endothelin-1 (ET-1; Jianglai Biology) were measured. The specific detection method was operated according to the instructions of the enzyme-linked immunosorbent assay (ELISA) kit.

Transcriptome sequencing
------------------------

The rats were decapitation after anesthetized by intraperitoneal injection of 10% chloral hydrate with 3.0 mg/kg. After sacrificed, hippocampus tissue of rat brain was quickly separated and placed on ice, and quickly frozen in liquid nitrogen. Three rats in each group were randomly selected for extracting total RNA from the hippocampus using RNA simple total RNA Extraction kit (Tiangen Biotech). Next, the library was built through NEBNext \<UltraTM RNA Library Prep Kit (Illumina). The library was diluted to 1.5 ng/uL and sequenced on the computer.

Difference analysis and protein--protein interaction (PPI) network
------------------------------------------------------------------

DESeq2 software (1.16.1) was used to analyze the differentially expression genes (DEGs) between the 2 comparison combinations. The Benjamini-Hochberg methods were used to adjust the *P* value to control the error detection rate. DESeq2 showed that genes with *P* value \<0.05 and \|log2foldchange\| \>1 were assigned to DEGs.

First, we map all differentially expressed genes into protein--protein interaction (PPI) networks. A PPI of changed genes in insomniac rats was constructed by extracting interaction pairs containing only these DEGs. Secondly, we are introducing the differential expression of PPIs and their genes into Cytoscape for display. Finally, the degree of genes was sequenced.

Enrichment analysis and gene-set enrichment analysis
----------------------------------------------------

Cluster Profiler (3.4.4) software was used for enrichment analysis using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) database for DEGs. Considering that terms with *P* value less than 0.05 are significantly enriched by DEGs.

We used gene-set enrichment analysis (GSEA) software to perform enrichment analysis on 4 groups of genes. First, we calculated the enrichment score (ES), which reflects the degree of enrichment of the set S at both ends of the entire ranking list L. In the second step, the significance of the enrichment score was evaluated. The statistical significance of the ES was estimated using a phenotype-based displacement test procedure. The third step was multiple hypothesis testing, which generally considers that the standardized enrichment score absolute value is \<1.0, and NOM *P*-value \<0.05 is a meaningful path entry.

Real-time quantitative polymerase chain reaction (RT-qPCR)
----------------------------------------------------------

Total RNA was reversely transcribed to cDNA with ImProm-II Reverse Transcription System (Promega). All cDNA sample was run in triplicates. The SYBR Green kit (Promega) was used for real time polymerase chain reaction (RT-PCR). The housekeeping gene, β-actin, was used as an internal control. Primer sequences are described in [Table 1](#t1-medscimonit-26-e921831){ref-type="table"}.

Western blot
------------

The extract of hippocampus tissue of rat brains was prepared by using the solution buffer (Thermo Scientific) containing the mixture of halt protease inhibitors. The total protein was loaded on sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE), separated by electrophoresis and transferred to polyvinylidene difluoride (PVDF) membrane. After incubation with 5% skimmed milk, the membrane was incubated with specific primary antibody (Bioswamp) at 4°C overnight. After 3 times of cleaning with phosphate-buffered saline plus Tween (PBS/Tween), it was incubated with secondary antibody combined with horseradish peroxidase (HRP). Finally, we use Fujifilm las-4000 mini (Fujifilm) to take pictures. The chemiluminescent signals recorded in a chemiluminescence imager (Chemidoc Touch, Biorad). β-actin antibody was used as control.

Statistical analysis
--------------------

SPSS16.0 statistical software package was used to process the data. One-way ANOVA was used for comparison between groups. The difference was statistically significant with *P*\<0.05.

Results
=======

Therapeutic effect of berberine on insomnia rats
------------------------------------------------

The study flowchart is presented in [Figure 1](#f1-medscimonit-26-e921831){ref-type="fig"}. First, we established an insomnia model in rats. Then, the relieving effect of berberine on insomnia model rats was investigated. Compared with the control group, the weight of insomnia rats decreased significantly. After berberine or diazepam treatment, the body weight of insomniac rats was considerably restored ([Figure 2A](#f2-medscimonit-26-e921831){ref-type="fig"}). Drug treatment significantly improved sleep quality in rats. In the pentobarbital sodium test, berberine and diazepam significantly reduced sleep latency and prolonged the sleep duration in insomniac rats ([Figure 2B](#f2-medscimonit-26-e921831){ref-type="fig"}). In addition, we evaluated the effect of drug treatment on memory ability of insomnia rats by water maze experiment. Insomniac rats treated with berberine and diazepam could find the platform more quickly, and the times of crossing the platform within the prescribed time increased significantly ([Figure 2C](#f2-medscimonit-26-e921831){ref-type="fig"}). In our study, we found that the moderate dose of berberine could alleviate the memory function of insomnia rats better. On the other hand, we also detected the expression of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), and endothelin-1 (ET-1) in rat plasma. The results showed that berberine and diazepam significantly reduced the pathological index of insomnia rats, especially the moderate dose of berberine ([Figure 2D](#f2-medscimonit-26-e921831){ref-type="fig"}). The results showed that even low doses of berberine sharply increased the body weight of insomniac rats. The salutary effects of moderate and high doses of berberine were similar.

Berberine regulated the expression of disordered genes in insomniac rats
------------------------------------------------------------------------

To evaluate the therapeutic effect of berberine, transcriptome sequencing was performed in the hippocampus of rats in 4 groups: blank control (BC), insomnia model (IMC), moderate dose berberine (HT), and diazepam (YT). Compared with the blank control rats, 198 DEGs were identified in insomnia rats. We believe that these genes are potential disorder genes for insomnia in rats ([Figure 3A](#f3-medscimonit-26-e921831){ref-type="fig"}). Then, we constructed a protein--protein interaction (PPI) network of disordered genes, and further identified key genes with high connectivity in the network, which included Erbb4, Erbb2, Ar, and Grin2a ([Table 2](#t2-medscimonit-26-e921831){ref-type="table"}, [Figure 3B](#f3-medscimonit-26-e921831){ref-type="fig"}). Importantly, we found that 124 of these potential disordered genes were regulated by berberine therapy. Another 99 genes are regulated by diazepam therapy ([Figure 3C](#f3-medscimonit-26-e921831){ref-type="fig"}). Surprisingly, after berberine treatment, the expression of Erbb4, Erbb2, Ar, and Grin2a was restored by comparative analysis. The expression of Erbb4, Ar, and Grin2a also recovered after diazepam treatment. Finally, the expression of key genes in rats was confirmed by qPCR ([Figure 3D](#f3-medscimonit-26-e921831){ref-type="fig"}) and western blot ([Figure 3E](#f3-medscimonit-26-e921831){ref-type="fig"}), which was consistent with the results of transcriptome sequencing. Berberine had a better effect on the expression of Erbb4, Erbb2, and Grin2a. These results suggest that berberine and diazepam can both play therapeutic roles by affecting the expression of insomnia-related genes.

Molecular regulation mechanisms of berberine in relieving insomnia
------------------------------------------------------------------

In order to further understand the molecular regulatory mechanism of berberine, we enriched and analyzed the disordered genes. Statistical results showed that the disordered genes were involved in 30 biological processes (BP), 11 cellular components (CC), 6 molecular functions (MF) and 6 KEGG pathways. These include key genes involved in nervous system development, response to drugs and other biological functions ([Figure 4A](#f4-medscimonit-26-e921831){ref-type="fig"}). Complement and coagulation cascades, ErbB signaling pathway, and other signaling pathways ([Figure 4B](#f4-medscimonit-26-e921831){ref-type="fig"}). Importantly, we found that ErbB pathway was activated by berberine and diazepam ([Figure 4C](#f4-medscimonit-26-e921831){ref-type="fig"}). This suggests that berberine and diazepam play a curative role mainly by affecting the nerve function and signaling pathway of rats.

Comparison of the metabolic mechanisms of berberine and diazepam by GSEA
------------------------------------------------------------------------

From the molecular mechanism of drug treatment, the targets of the 2 drugs are comparable. In order to compare the time of drug action, we further screened metabolic pathways involved in drug action by GSEA. Seventeen of the 115 signaling pathways in which genes participated in the hippocampus of rats after berberine treatment were metabolically related. Twelve of 108 signaling pathways that changed after diazepam treatment were metabolically related ([Table 3](#t3-medscimonit-26-e921831){ref-type="table"}, [Figure 5](#f5-medscimonit-26-e921831){ref-type="fig"}). The results showed that berberine might be absorbed faster than diazepam, but the duration of its effect was shorter.

Discussion
==========

Insomnia, as a disease, poses serious risks to the development of cardiovascular and psychiatric diseases, including cognitive deficits \[[@b26-medscimonit-26-e921831]\]. Drug therapy for insomnia has been changing over the past decades. This is mainly attributed to the growing concern about overuse of drugs \[[@b36-medscimonit-26-e921831]\], the change in prescription habits \[[@b37-medscimonit-26-e921831]\], and the increased access to non-drug treatment options \[[@b38-medscimonit-26-e921831]\]. Western drugs for insomnia can easily lead to addiction and other side effects \[[@b39-medscimonit-26-e921831]\]. Therefore, exploring the therapeutic effect and mechanism of traditional Chinese medicine on sleep disorders has become an important research direction. Herein, we evaluated the therapeutic effect of berberine on insomnia rats. Compared with diazepam, berberine had better therapeutic effect on memory recovery. High dosage of berberine did not noticeably increase the body weight of insomniac rats, which might have a bearing on the inhibition of appetite and stomach by high berberine dose. In addition, berberine treatment also alleviated the imbalance of cardiovascular related factors in insomnia rats, and the effect was better than diazepam.

On the other hand, we identified the therapeutic mechanism of berberine by transcriptome sequencing in the hippocampus of 4 groups of rats. We believe that the DEGs between insomnia rats and control rats are disease-related genes of insomnia. Through the PPI network, we identified the core genes in the disordered gene network. After berberine and diazepam treatment, the expression of some genes in insomniac rats changed. We believe that these genes are related to the therapeutic effect of drugs. Surprisingly, the expression of core genes was altered after berberine treatment. Erbb4 is an important NRG-1 receptor involved in many key functions such as neurodevelopment and synaptic plasticity \[[@b40-medscimonit-26-e921831],[@b41-medscimonit-26-e921831]\]. Nerves and synapses were significantly correlated with sleep activity \[[@b42-medscimonit-26-e921831]\]. ErbB 4 plays a key role in regulating the function of cortical-thalamic reticular nucleus (TRN) -thalamic circuit \[[@b43-medscimonit-26-e921831]\]. TRN is critical in the sleep process \[[@b44-medscimonit-26-e921831]\]. Reduced activity of TRN neurons may explain abnormal sleep function \[[@b45-medscimonit-26-e921831]\]. Erbb2 receptor tyrosine kinase plays a major role in early development and regulation of various cell behaviors \[[@b46-medscimonit-26-e921831]\]. It has been found that androgen receptor (Ar) in the main circadian clock of suprachiasmatic nucleus regulates the effect of light on male activity \[[@b47-medscimonit-26-e921831]\]. In addition, changes in GluN2A, a N-methyl-d-aspartate receptor (NMDAR) subunit encoded by GRIN2A, are associated with neurodevelopmental disorders and are critical to sleep-related physiological and pathological processes \[[@b48-medscimonit-26-e921831],[@b49-medscimonit-26-e921831]\]. The aforementioned analysis showed that berberine can achieve therapeutic effect by influencing the expression of key disorder factors.

Our research showed that berberine mainly affects neurological functions and signaling pathways in the treatment process. This is consistent with previous studies that showed that berberine has central nervous system activity \[[@b50-medscimonit-26-e921831]\]. Berberine has also been shown to have neuroprotective effects on learning and memory impairment in rats with severe diffuse axonal injury by inhibiting inflammation, angiogenesis, and apoptosis \[[@b51-medscimonit-26-e921831]\]. The results of one study showed that berberine affected ErbB signaling pathway in insomniac rats, and it could affect the production of several sleep-promoting substances \[[@b52-medscimonit-26-e921831]\]. EGFR, a member of the ErbB signaling pathway, can play a promotive role in Drosophila sleep \[[@b52-medscimonit-26-e921831]\]. In addition, proteins regulated by coagulation cascades will affect the pathophysiology of the central nervous system (CNS) \[[@b53-medscimonit-26-e921831]\]. The activation of complement cascades in peripheral blood significantly affected the circadian rhythm \[[@b54-medscimonit-26-e921831]\]. Importantly, berberine increased the metabolic rate of insomnia rats compared with diazepam. Not only can berberine exert its pharmacodynamics faster, but also improve the overall health status of insomnia rats \[[@b55-medscimonit-26-e921831]\]. In contrast, berberine has more advantages to relieve insomnia in rats.

Conclusions
===========

Our study results confirm that berberine can improve body weight, learning and memory ability, and sleep quality of insomniac rats. It has neuroprotective and health-enhancing effects on insomnia rats. These results suggest that berberine is a potentially effective drug for the treatment of insomnia to consider in the future.
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![The effect of berberine on the clinical indexes of insomnia in rats. (**A**) Berberine and diazepam restored the body weight of insomnia rats. (**B**) Berberine and diazepam reduced the sleep latency of insomnia rats and prolonged the sleep duration in pentobarbital sodium test. (**C**) In the water maze experiment, the time of finding the platform in insomniac rats treated with berberine and diazepam decreased, and the number of times of crossing the platform increased. (**D**) The expression of ANP, BNP, and ET-1 in insomnia rats after berberine and diazepam treatment were decreased. \* *P*\<0.05, \*\* *P*\<0.01, \*\*\* *P*\<0.001 versus model group; ^\#^ *P*\<0.05, ^\#\#^ *P*\<0.01 versus diazepam group. ANP -- atrial natriuretic peptide; BNP -- B-type natriuretic peptide; ET-1 -- endothelin-1.](medscimonit-26-e921831-g002){#f2-medscimonit-26-e921831}

![Berberine regulates gene expression in hippocampus of insomnia rats. (**A**) Transcription group sequencing identified differentially expressed genes (volcanic and thermal maps) in insomniac rats compared with blank control rats. Red nodes represent upregulated genes and blue nodes represent downregulated genes. (**B**) The connectivity of disordered genes was screened by PPI network. The larger the node, the higher the connectivity of the gene. Red nodes represent upregulated genes and green nodes represent downregulated genes. (**C**) Effects of berberine and diazepam on the expression of disordered genes in insomniac rats. (**D**) qPCR was used to verify the expression of core genes in rats. (**E**) Western blot was used to verify the expression of core genes in rats. \*\* *P*\<0.01, \*\*\* *P*\<0.001 versus model group, ^\#^ *P*\<0.05, ^\#\#^ *P*\<0.01 versus diazepam group. PPI -- protein--protein interaction; qPCR -- quantitative polymerase chain reaction.](medscimonit-26-e921831-g003){#f3-medscimonit-26-e921831}

![Enrichment analysis was used to identify the molecular regulatory mechanism of berberine therapy. (**A**) The key genes involved in GO function in berberine therapy. (**B**) The key genes involved in KEGG signaling pathway in berberine therapy. (**C**) Phosphorylation of ErbB2 and ErbB4 proteins. \* *P*\<0.05, \*\* *P*\<0.01, \*\*\* *P*\<0.001 versus model group. GO -- Gene Ontology; KEGG -- Kyoto Encyclopedia of Genes and Genomes.](medscimonit-26-e921831-g004){#f4-medscimonit-26-e921831}

![GSEA identified metabolic signaling pathways associated with berberine and diazepam treatment. (**A**) Berberine treatment activates metabolic signaling pathways. (**B**) Diazepam activate metabolic signaling pathways. Abbreviations: GSEA, gene-set enrichment analysis.](medscimonit-26-e921831-g005){#f5-medscimonit-26-e921831}

###### 

Primer sequences of key genes.

  -------- --------- ------------------------
  Erbb4    Forward   CACAGCCCTCCTCCTGCCTAC
  Erbb4    Reverse   GCCTCTGGTATGGTGCTGGTTG
  Erbb2    Forward   GGGCTGGCTCCGATGTGTTTG
  Erbb2    Reverse   CCGCTGTAGAGGGCTGAGGTC
  Ar       Forward   GGCAGCAGTGAAGCAGGTAGC
  Ar       Reverse   GGACAGAGCGAGCGGAAAGTTG
  Grin2a   Forward   GTGTGATGCCTGTCTGCGGATG
  Grin2a   Reverse   CTGGAGGGCGTTGTTCTGTGAC
  -------- --------- ------------------------

###### 

Connectivity in protein--protein interaction network of disordered genes.

  Name     Degree   log2 fold change   *P*-value
  -------- -------- ------------------ -----------
  Erbb4    6        −2.38692           2.39E-08
  Erbb2    5        −2.30426           0.030524
  Ar       4        −2.8244            1.00E-10
  Grin2a   4        −2.90201           2.06E-05

###### 

Metabolic signaling pathways involving genes expressed in rat hippocampus after drug treatment.

  ------------------------------------------------------------------------------------------------
  Berberine treatment                            Diazepam treatment
  ---------------------------------------------- -------------------------------------------------
  KEGG glycerolipid metabolism                   KEGG inositol phosphate\
                                                 KEGG metabolism

  KEGG inositol phosphate metabolism             KEGG glycerolipid metabolism

  KEGG glycerophospholipid metabolism            KEGG beta alanine metabolism

  KEGG ether lipid metabolism                    KEGG glycerophospholipid metabolism

  KEGG propanoate metabolism                     KEGG sphingolipid metabolism

  KEGG sphingolipid metabolism                   KEGG purine metabolism

  KEGG purine metabolism                         KEGG cysteine and methionine metabolism

  KEGG drug metabolism other enzymes             KEGG propanoate metabolism

  KEGG porphyrin and chlorophyll metabolism      KEGG alanine aspartate and glutamate metabolism

  KEGG starch and sucrose metabolism             KEGG starch and sucrose metabolism

  KEGG galactose metabolism                      KEGG nicotinate and nicotinamide metabolism

  KEGG alpha linolenic acid metabolism           KEGG tryptophan metabolism

  KEGG beta alanine metabolism                   

  KEGG glycine serine and threonine metabolism   

  KEGG butanoate metabolism                      

  KEGG nicotinate and nicotinamide metabolism    

  KEGG linoleic acid metabolism                  
  ------------------------------------------------------------------------------------------------
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